Business
New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3
- Data Generated to Date Support Potential for Aclaris’ ATI-2138 to Impact Several Human Inflammatory Diseases - WAYNE, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) --
About this update from Aclaris Therapeutics, Inc.
[{"type":"text","content":"- Data Generated to Date Support Potential for Aclaris’ ATI-2138 to Impact Several Human Inflammatory Diseases - WAYNE, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced the availability of a new publication describing the unique properties of Aclaris Therapeutics’ ATI-2138, a novel investigational covalent inhibitor of interleukin-2-inducible T cell kinase (ITK) and Janus kinase 3 (JAK3) in development for the treatment of autoimmune and inflammatory diseases. This was published in The Journal of Pharmacology and Experimental Therapeutics and can be found here. “This publication provides important clinical and non-clinical evidence of the potential for ATI-2138 to be a best-in-class inhibitor of key signal transduction kinases as a result of its unique mechanism of action,” said Dr. Joseph Monahan, Ph.D., Aclaris’ Chief Scientific Officer. “ATI-2138 potently and selectively blocks both ITK and JAK3. Through this mechanism, ATI-2138 has been shown in preclinical studies to effectively inhibit Th1, Th2 and Th17 cell activity, which are key T cells involved in a wide range of autoimmune, chronic inflammatory and allergic diseases, including atopic dermatitis (AD), alopecia areata, and vitiligo. In addition, JAK inhibitors have been approved in multiple diseases including AD. Data generated to date support our ongoing clinical efforts including our ongoing Phase 2a trial of ATI-2138 in AD.” ITK regulates T cell receptor signal transduction and inhibition of this kinase can affect T cell differentiation and activation. JAK3 is a key signal transduction kinase that forms a heterodimer with JAK1, modulates JAK1 phosphorylation of signal transducer and activator of transcription 5 (STAT5), and regulates cytokines that signal through the IL-2 receptor common gamma chain (IL-2Rγc) to affect lymphocyte proliferation and activation (Leonard and O'Shea, 1998; Rochman et al., 2009; Agashe et al., 2022). The publication, entitled “Characterization of the dual ITK/JAK3 small molecule covalent inhibitor ATI-2138,” describes in vitro and in vivo assessments and the clinical translation of ATI-2138 on ITK and JAK3 signaling. It describes the evaluation of the efficacy of ATI-21...